Drug Development
Our understanding of the causes of cancer informs our efforts to develop effective therapies. Mutations of the BRAF gene that result in an aberrant KIAA1549-BRAF fusion protein and subsequent dysregulation of the RAS/RAF/MEK signaling pathway occur in a large number of pediatric low-grade gliomas. This pathway is therefore a good candidate pathway for therapeutic targeting. […]